Fundraising FoxNeuBase Therapeutics
Pittsburgh, US · Delaware corporation · 1 known investors
Find your way into NeuBase Therapeutics
Sign up to see every warm intro you have to NeuBase Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the NeuBase Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
DS
Dietrich StephanFounder
TB
Todd BranningExecutive
SB
Sam BackenrothExecutive
IT
Irach TaraporewalaExecutive
ER
Eric RichmanNamed on SEC filing
FP
Franklyn PrendergastNamed on SEC filing
GM
Gerald McDougallNamed on SEC filing
DG
Dov GoldsteinNamed on SEC filing
Board
OH
Orin HirschmanBoard director
JA
June AlmenoffBoard director
TR
Thomas RiedhammerBoard director
IG
Ira GreensteinBoard director
Investors · 1
Cyto VenturesreportedPittsburgh
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$15.8M disclosed across 4 rounds · 2013–2023
▶$5MraisedJul 2023 · 1 investors · BiotechnologyRule 506(b)
▶$5MraisedJul 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eric RichmanDirector
- Todd BranningExecutive Officer
- Dietrich StephanExecutive Officer, Director
- Franklyn PrendergastDirector
- Gerald McDougallDirector
- Dov GoldsteinDirector
- Offering amount
- $5M
- Amount sold
- $5M
- Sales commissions
- $482.4K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50KraisedDec 2014 · 1 investors · BiotechnologyRule 506(b)
▶$50KraisedDec 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Irach TaraporewalaExecutive Officer, Director
- Orin HirschmanDirector
- Thomas RiedhammerDirector
- June AlmenoffDirector
- Sam BackenrothExecutive Officer
- Ira GreensteinDirector
- Offering amount
- $50K
- Amount sold
- $50K
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.2MraisedJun 2014 · 1 investors · BiotechnologyRule 506(b)
▶$10.2MraisedJun 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sam BackenrothExecutive Officer
- June AlmenoffDirector
- Ira GreensteinDirector
- Irach TaraporewalaExecutive Officer, Director
- Orin HirschmanDirector
- Thomas RiedhammerDirector
- Offering amount
- $25.2M
- Amount sold
- $10.2M
- First sale
- May 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$569.6KraisedJan 2014 · 3 investors · BiotechnologyRule 506(b)
▶$569.6KraisedJan 2014 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- June AlmenoffDirector
- Orin HirschmanDirector
- Thomas RiedhammerDirector
- Ira GreensteinDirector
- Sam BackenrothExecutive Officer
- Irach TaraporewalaExecutive Officer, Director
- Offering amount
- $569.6K
- Amount sold
- $569.6K
- First sale
- Dec 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who founded NeuBase Therapeutics?
- NeuBase Therapeutics was founded by Dietrich Stephan.
- Who are NeuBase Therapeutics's investors?
- NeuBase Therapeutics's investors include Cyto Ventures.
- How much funding has NeuBase Therapeutics raised?
- NeuBase Therapeutics has disclosed $15.8M raised across 4 rounds.
- Where is NeuBase Therapeutics headquartered?
- NeuBase Therapeutics is headquartered in Pittsburgh, US.